Tumor immunotherapies, including chimeric antigen receptor T-cell immunotherapy and anti-PD-1/PD-L1/CTLA-4 monoclonal antibodies, have received a lot of focus as an integral aspect of combination therapy in recent years [39]. This evidence concerns the gene CTLA4 and neoplasm.